Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Ayman Megally"'
Autor:
Shigeo Muro, Tomotaka Kawayama, Hisatoshi Sugiura, Munehiro Seki, Elizabeth A. Duncan, Karin Bowen, Jonathan Marshall, Ayman Megally, Mehul Patel
Publikováno v:
Respiratory Research, Vol 25, Iss 1, Pp 1-11 (2024)
Abstract Background Japanese guidelines recommend triple inhaled corticosteroid (ICS)/long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA) therapy in patients with chronic obstructive pulmonary disease (COPD) and no concurrent asth
Externí odkaz:
https://doaj.org/article/991826ae90dd4b509303175b73806b5b
Autor:
Claire Emson, Sarah Diver, Latifa Chachi, Ayman Megally, Cherrie Small, John Downie, Jane R. Parnes, Karin Bowen, Gene Colice, Chris E. Brightling
Publikováno v:
Respiratory Research, Vol 21, Iss 1, Pp 1-9 (2020)
Abstract Background Patients with severe, uncontrolled asthma, particularly those with a non-eosinophilic phenotype, have a great unmet need for new treatments that act on a broad range of inflammatory pathways in the airway. Tezepelumab is a human m
Externí odkaz:
https://doaj.org/article/c2a1c95e81a5415ba02a0c5caa7789fd
Autor:
Claire Emson, Sally E. Wenzel, Jane R. Parnes, James Johnston, Sarah Diver, Christopher E. Brightling, Latifa Khalfaoui, Ayman Megally, Nestor Molfino, Michael E. Wechsler, Gene L. Colice, Andrew Menzies-Gow
Publikováno v:
The Lancet Respiratory Medicine. 9:1299-1312
Summary Background Tezepelumab is a human monoclonal antibody that blocks the activity of thymic stromal lymphopoietin (TSLP), an epithelial cell-derived cytokine. In phase 2b and 3 studies, tezepelumab significantly reduced exacerbations versus plac
Publikováno v:
Journal of Asthma and Allergy
Sady Alpizar,1 Ayman Megally,2 Claudia Chen,3 Abhi Raj,4 John Downie,5 Gene Colice2 1Clinical Research Trials of Florida, Inc., Tampa, FL, USA; 2Late-Stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD
Autor:
Jane R. Parnes, L. Khalfaoui, Gene L. Colice, Andrew Menzies-Gow, J. Johnston, Michael E. Wechsler, Sally E. Wenzel, Sarah Diver, Christopher E. Brightling, Ayman Megally, John Downie, Claire Emson
Publikováno v:
TP10. TP010 CLINICAL AND POPULATION-LEVEL STUDIES OF ASTHMA.
Autor:
Nicholas White, Jihong Wang, Gillian Hunter, Yuling Li, Ayman Megally, Weichen Xu, Gene L. Colice, Martin Braddock, Mats Carlsson
Publikováno v:
Drug Safety
Introduction Tralokinumab is a monoclonal antibody (mAb) that neutralizes interleukin (IL)-13, a cytokine involved in the pathogenesis of asthma. Objective The objectives of this study were to characterize the potential immunogenic properties of tral
Autor:
Karin Bowen, Latifa Chachi, Claire Emson, Gene L. Colice, Christopher E. Brightling, Jane R. Parnes, Sarah Diver, Ayman Megally, John Downie, Cherrie Small
Publikováno v:
Respiratory Research
Respiratory Research, Vol 21, Iss 1, Pp 1-9 (2020)
Respiratory Research, Vol 21, Iss 1, Pp 1-9 (2020)
Background Patients with severe, uncontrolled asthma, particularly those with a non-eosinophilic phenotype, have a great unmet need for new treatments that act on a broad range of inflammatory pathways in the airway. Tezepelumab is a human monoclonal
Autor:
Ayman Megally, John Downie, Rainard Fuhr, Yanan Zheng, Lubna Abuqayyas, Gene L. Colice, Kinga Sałapa
Publikováno v:
Clinical Therapeutics. 43:142-155.e5
Purpose Tezepelumab is an anti–thymic stromal lymphopoietin monoclonal antibody therapeutic in development for patients with severe, uncontrolled asthma. In ongoing Phase III studies, tezepelumab is administered via subcutaneous (SC) injections usi